- Home
- OBIO vs EDIT Comparison
OBIO vs EDIT Comparison
Compare OBIO & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OBIO | EDIT |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.2M | 206.0M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | OBIO | EDIT |
|---|---|---|
| Price | $3.95 | $1.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $14.25 | $4.50 |
| AVG Volume (30 Days) | 219.1K | ★ 1.8M |
| Earning Date | 11-10-2025 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,818,000.00 | ★ $46,383,000.00 |
| Revenue This Year | $36.66 | N/A |
| Revenue Next Year | $2.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.46 | N/A |
| 52 Week Low | $2.20 | $0.91 |
| 52 Week High | $6.02 | $4.54 |
Technical Indicators
Market Signals| Indicator | OBIO | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 45.48 | 39.74 |
| Support Level | $3.46 | $1.66 |
| Resistance Level | $4.24 | $2.11 |
| Average True Range (ATR) | 0.31 | 0.15 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 45.70 | 21.08 |
Price Performance
Historical ComparisonAbout OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.